NCT05471843进行中（未招募）1 期
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
BeiGene104 个研究点 分布在 6 个国家目标入组 125 人开始时间: 2022年9月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 125
- 试验地点
- 104
- 主要终点
- Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
研究概览
简要总结
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of MCL
- •Prior systemic treatments for MCL (at least one line of anti-cluster of differentiation 20 (anti-CD20) based immune or chemoimmunotherapy and at least one kind of covalent or non-covalent adequate Bruton Tyrosine Kinase (BTK) inhibitor).
- •Relapsed/refractory disease
- •Presence of measurable disease
- •Availability of archival tissue confirming diagnosis of MCL, or willing to undergo fresh tumor biopsy
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or
- •Adequate organ function
排除标准
- •Known central nervous system involvement by lymphoma
- •Prior malignancy other than MCL within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer.
- •Prior exposure to a BCL-2 inhibitor (eg, venetoclax/ABT-199).
- •Prior autologous stem cell transplant within the last 3 months; or prior autologous chimeric antigen receptor T-cell therapy within the last 3 months; or prior allogeneic stem cell transplant within the last 6 months or currently has an active graft-vs-host disease requiring the use of immunosuppressants.
- •Clinically significant cardiovascular disease.
- •Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.
- •Active fungal, bacterial or viral infection requiring systemic treatment.
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Single Arm
Experimental
Participants will receive sonrotoclax
干预措施: BGB-11417 (Drug)
结局指标
主要结局
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
时间窗: Up to 1 Year
Part 1: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation.
时间窗: Up to 5 Years
Part 1: Number of participants experiencing tumor lysis syndrome (TLS) relevant events
时间窗: Up to 5 Years
Part 2: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)
时间窗: Up to 4 Years
Defined as the proportion of participants who achieved a complete response (CR), or partial response (PR) per the Lugano Classification
次要结局
- Part 1: Single Dose Area Under the Plasma Concentration Time Curve (AUC)(Up to 2 Years)
- Part 1: Single Dose Maximum Observed Plasma Concentration (Cmax)(Up to 2 Years)
- Part 1: Single Dose Time to reach Cmax (Tmax)(Up to 2 Years)
- Part 1: Steady State Area Under the Plasma Concentration Time Curve (AUC)(Up to 2 Years)
- Part 1: Steady State Maximum Observed Plasma Concentration (Cmax)(Up to 2 Years)
- Part 1: Steady State Trough Plasma Concentration (CTrough)(Up to 2 Years)
- Part 1: Steady State Time to reach Cmax (Tmax)(Up to 2 Years)
- Overall Response Rate (ORR) as assessed by investigator(Up to 4 Years)
- Duration of Response (DOR) as assessed by investigator and IRC(Up to 4 Years)
- Progression Free Survival (PFS) as assessed by investigator and IRC(Up to 4 Years)
- Time to Response (TTR) as assessed by investigator and IRC(Up to 4 Years)
- Overall Survival (OS)(Up to 4 Years)
- Part 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation.(Up to 4 Years)
- Part 2: Number of participants with clinically significant changes from baseline in vital signs(Up to 4 Years)
- Part 2: Number of participants with clinically significant changes from baseline in clinical laboratory values(Up to 4 Years)
- Part 2: Number of Participants With Clinically Significant Physical Examination Findings(Up to 4 Years)
- Part 2: Participant Reported Outcomes as measured by NFLymSI-18(Up to 4 Years)
- Part 2: Participant Reported Outcomes as measured by EQ-5D-5L questionnaires(Up to 4 Years)
研究者
研究点 (104)
Loading locations...
相似试验
进行中（未招募）
1 期
Study of BGB-11417 in Adult Participants With Mature B-cell MalignanciesMature B-cell MalignanciesNCT04883957BeiGene64
已完成
2 期
A Study of GSK2118436 in BRAF Mutant Metastatic MelanomaMelanomaNCT01153763GlaxoSmithKline92
进行中（未招募）
2 期
Study of AZD2811 + Durvalumab in ES-SCLCSmall-Cell Lung CancerNCT04745689AstraZeneca31
招募中
1 期
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCLLarge B-cell LymphomaNCT06375733Genfleet Therapeutics (Shanghai) Inc.51
已完成
1 期
To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.Infections, BacterialNCT02853435GlaxoSmithKline48